de

Registrieren
Investieren birgt Risiken und ist nicht für alle Anleger geeignet.
Home・Aktien・AstraZeneca PLC
Search

AstraZeneca PLC

Geschlossen

Branche Gesundheitswesen

11,964

Buy

Kursupdate 3. Okt. 2024, 15:29 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11920

Max

12082

Schlüsselkennzahlen

By Trading Economics

Einkommen

-252M

1.9B

Verkäufe

258M

13B

KGV

Branchendurchschnitt

38.58

113.916

EPS

1.98

Gewinnspanne

14.894

EBITDA

-349M

4.1B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+14.63 upside

Dividenden

By Dow Jones

Nächstes Ergebnis

12. Nov. 2024

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

6.1B

186B

Vorheriger Eröffnungskurs

11964

Vorheriger Schlusskurs

11964

Nachrichtenstimmung

By Acuity

33%

67%

106 / 366 Ranking in Healthcare

AstraZeneca PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Sept. 2024, 09:29 UTC

Wichtige Markttreiber

AstraZeneca Shares Slump After Cancer Drug Misses Key Target

DJ

Lesen

25. Juli 2024, 09:17 UTC

Ergebnisse

AstraZeneca Raises Guidance After Results Beat Market Expectations -- Update

DJ

Lesen

25. Juli 2024, 06:48 UTC

Ergebnisse

AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations

DJ

Lesen

12. Sept. 2024, 17:01 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

DJ

Lesen

12. Sept. 2024, 11:00 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

DJ

Lesen

10. Sept. 2024, 13:08 UTC

Market Talk

AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk

DJ

Lesen

9. Sept. 2024, 07:56 UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

DJ

Lesen

5. Sept. 2024, 13:00 UTC

Top News

China Detains AstraZeneca Employees Over Alleged Transport of Unapproved Drug -- WSJ

DJ

Lesen

29. Juli 2024, 10:30 UTC

Top News

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

DJ

Lesen

25. Juli 2024, 13:20 UTC

Ergebnisse

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

DJ

Lesen

25. Juli 2024, 09:21 UTC

Market Talk
Ergebnisse

AstraZeneca's Guidance Lift Is Conservative; Risks to Upside -- Market Talk

DJ

Lesen

25. Juli 2024, 07:05 UTC

Market Talk
Ergebnisse

AstraZeneca Guidance Raise Signals Portfolio Potential -- Market Talk

DJ

Lesen

25. Juli 2024, 06:06 UTC

Ergebnisse

AstraZeneca Increased Interim Dividend by 7c to $1.00

DJ

Lesen

25. Juli 2024, 06:04 UTC

Ergebnisse

AstraZeneca Had Seen Core EPS Grow by Low Double-Digit to Low Teens Percentage Range

DJ

Lesen

25. Juli 2024, 06:04 UTC

Ergebnisse

AstraZeneca Had Seen Total Revenue Grow by Low Double-Digit to Low Teens Percentage Range

DJ

Lesen

25. Juli 2024, 06:04 UTC

Ergebnisse

AstraZeneca Sees Core EPS Growth in 2024 by Mid Teens Percentage Range At Constant Currency

DJ

Lesen

25. Juli 2024, 06:04 UTC

Ergebnisse

AstraZeneca Sees Total Revenue Growth in 2024 by Mid Teens Percentage Range At Constant Currency

DJ

Lesen

25. Juli 2024, 06:03 UTC

Ergebnisse

AstraZeneca Raises 2024 View

DJ

Lesen

25. Juli 2024, 06:02 UTC

Ergebnisse

AstraZeneca 2Q Revenue Consensus Was $12.7B

DJ

Lesen

25. Juli 2024, 06:02 UTC

Ergebnisse

AstraZeneca 2Q Core EPS Consensus Was $1.95

DJ

Lesen

25. Juli 2024, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q Adj EPS $1.98

DJ

Lesen

25. Juli 2024, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q Pretax Pft $2.4B

DJ

Lesen

25. Juli 2024, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q Rev $12.94B

DJ

Lesen

25. Juli 2024, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q Oper Pft $2.75B

DJ

Lesen

25. Juli 2024, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q Net Pft $1.93B

DJ

Lesen

25. Juli 2024, 06:00 UTC

Ergebnisse

AstraZeneca PLC 2Q EPS $1.24

DJ

Lesen

15. Juli 2024, 06:04 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone

DJ

Lesen

15. Juli 2024, 06:04 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone

DJ

Lesen

15. Juli 2024, 06:02 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca: Acquisition Includes $800M Upfront at Deal Closing

DJ

Lesen

15. Juli 2024, 06:02 UTC

Akquisitionen, Fusionen, Übernahmen

AstraZeneca: Amolyt Pharma's Total Consideration of Up to $1.05B

DJ

Lesen

AstraZeneca PLC Prognose

Kursziel

By TipRanks

14.63% Vorteil

12-Monats-Prognose

Durchschnitt 13,693.43 GBX  14.63%

Hoch 20,000 GBX

Tief 10,500 GBX

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AstraZeneca PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

12

Buy

3

Halten

3

Sell

Basierend auf 18 Analysten, die in den letzten 3 Monaten Aktienbewertungen für AstraZeneca PLC – Dist abgegeben haben.

Stimmung

By Acuity

106 / 366 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

$

Über AstraZeneca PLC

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.